A Handful Of Predictions On The Future Of the NLG919

The institutional review board of each participating centre approved this study and informed consent for study participation was obtained from each patient or legal guardian. BM samples were analysed using 4-colour [HLA-DR-FITC (fluorescein isothiocyanate)/CD19-PE (phycoerythrin)/CD20-PerCP (peridinin chlorophyll)/CD10-APC (allophycocyanin)] or 6-colour [CD3-FITC/CD16��56-PE/CD45-PerCP/CD10-PE-Cy7 (cyanin 7)/CED19-APC/CD20-APC-Cy7] immunostains. The proportion of BCPs within the nucleated cells was determined using Infinicyt software (Cytognos, Salamanca, Spain) based on scatter position and co-expression of CD19 and CD10. Additionally, CD45dim, CD3? and CD16��56? were used when available. The BCP-positive group was defined as patients who had ��0��01% BCPs in the BM after induction therapy. At least 50?000 cells were counted per sample and in majority of the samples (68%) at least 100?000 cells were counted. In all BCP-negative patients at least 100?000 cells were http://www.selleckchem.com/products/pexidartinib-plx3397.html acquired, sufficient to detect the presence of BCP. MRD levels were analysed by flow cytometry as previously reported (van der Velden et?al, 2010). Cohort characteristics were compared using Chi-Square and Fisher's Exact for categorical variables and Mann-Whitney U for continuous variables. BCP-positive and BCP-negative patients were plotted in a cumulative incidence of relapse (CIR) curve (Kim, 2007) and compared with a Gray test. Confidence intervals for the five-year CIR are provided. Hazard ratios were estimated using Cox regression and 95% confidence interval (95% CI) http://www.selleckchem.com/products/bmn-673.html are reported. BCP levels and age were correlated using Spearman's rho. Healthy BM controls were compared using http://www.selleck.cn/products/nlg919.html Mann�CWhitney U. P values